Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Cognitive function in obese individuals improves substantially with weight loss alone, but the direct central GLP-1R effects may contribute additional benefit beyond what weight reduction alone would predict
People with serious gastrointestinal conditions, like gastroparesis or uncontrolled inflammatory bowel disease, should not take GLP-1 medications
GLP-1RAs have been shown to reduce blood pressure, although the exact mechanism is unknown
A 2021 phase 2 trial published in The New England Journal of Medicine showed semaglutide 2.4 mg achieved NASH resolution without worsening fibrosis in 59% of patients versus 17% on placebo (Newsome et al., NEJM 2021)
Cardiovascular effects: Phase 2 trial data indicate that retatrutide was associated with modest increases in resting heart rate, consistent with observations seen with other GLP-1 receptor agonists
US$ 23.51
US$ 25.74
US$ 28.98
US$ 26.27
US$ 27.84
US$ 22.91
US$ 27.74
US$ 25.02
US$ 26.86
US$ 26.65
